Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. At 6, the average consequence score sits above the same-window beat average of 5.7. We currently track 1 Biotech story that mention eXoZymes Inc., all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering eXoZymes Inc.. Shared-story counts are live from our verified record — not editorial picks.
eXoZymes lands a high-profile DOE grant to develop AI digital twins for cell-free enzyme manufacturing. The 9-month collaboration with Lawrence Berkeley Lab could slash process development timelines and unlock faster routes for nutraceuticals and novel therapeutics.
Source: californiatelegraph.com · hawaiitelegraph.com
eXoZymes Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
